Perception of potential harm and benefits of HIV vaccine trial participation: A qualitative study from urban Tanzania

Autoři: Edith A. M. Tarimo aff001;  Joel Ambikile aff002;  Patricia Munseri aff003;  Muhammad Bakari aff003
Působiště autorů: Department of Nursing Management, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania aff001;  Department of Clinical Nursing, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania aff002;  Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania aff003
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0224831



The development of an effective preventive HIV vaccine is the best-known option to halt incident HIV infections. Participants in HIV vaccine trials may possess expectations shaped by existing socio-cultural contexts that are important to understand to allow for improved trial design. Here, we describe post-phase I/II HIV vaccine trial perceptions within participating communities in Dar es Salaam, Tanzania.

Materials and methods

This descriptive qualitative study was conducted in May 2016. We conducted eight focus group discussions, each consisting of 5 to 12 participants. Four groups comprised of the past phase I/II HIV vaccine trial participants and four groups involved those who did not participate. We used a thematic analysis approach.


Ongoing concerns existed among non-vaccine trial participants who believed that those who participated in HIV vaccine trials were infected with HIV. Limited post-HIV vaccine trial result dissemination, the pre-existing negative beliefs about vaccines, and experiences from other previous medical experiments fueled these concerns. The participants anticipated that broader dissemination of facts regarding HIV vaccine trials using media, former volunteers, and flyers would reduce the reported concerns. In contrast, some participants embraced the benefits gained through participating in HIV vaccine trials. HIV vaccine trial participants appreciated trial interventions, such as health status check-ups, knowledge acquisition, and facilitation of access to medical services. They envisioned mutual benefits in the form of community protection and capacity building among the local scientists.


The future conduct of HIV vaccine trials in Tanzania requires wider community dissemination of information and post-trial feedback to alleviate concerns among the participating communities. Interventions such as medical services may represent essential incentives to the HIV vaccine trial volunteers. In future HIV vaccine trials, it is crucial to boost individual and perceived mutual benefits.

Klíčová slova:

AIDS – HIV infections – HIV vaccines – Police – Prisons – Vaccination and immunization – Vaccines


1. International AIDS Vaccine Initiative [IAVI]. Database of AIDS Vaccine Candidate in Clinical Trials. [Accessed 3/3/2018]

2. Wolfe RM, Sharp LK. Anti-vaccinationists past and present. BMJ. 2002 Aug 24;325[7361]:430–2. doi: 10.1136/bmj.325.7361.430 12193361

3. Olpinski M. Anti-Vaccination Movement and Parental Refusals of Immunization of Children in USA. Polish Pediatric Society Elsevier Urban and Partner. 2012;87:381–5.

4. Poland GA, Jacobson RM. Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine. 2001 Mar 21;19[17–19]:2440–5. doi: 10.1016/s0264-410x(00)00469-2 11257375

5. Gangarosa EJ, Galazka AM, Wolfe CR, Phillips LM, Gangarosa RE, Miller E, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet. 1998 Jan 31;351[9099]:356–61. doi: 10.1016/s0140-6736(97)04334-1 9652634

6. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998 Feb 28;351[9103]:637–41. doi: 10.1016/s0140-6736(97)11096-0 9500320

7. DeStefano F, Bodenstab HM, Offit PA. Principal Controversies in Vaccine Safety in the United States. Clinical Infectious Diseases. 2019;69[4]:726–31.

8. Miller L, Reynolds J. Autism and vaccination-the current evidence. J Spec Pediatr Nurs. 2009 Jul;14[3]:166–72. doi: 10.1111/j.1744-6155.2009.00194.x 19614825

9. Streefland PH. Introduction of a HIV vaccine in developing countries: social and cultural dimensions. Vaccine. 2003 Mar 28;21[13–14]:1304–9. doi: 10.1016/s0264-410x(02)00685-0 12615424

10. Newman PA, Seiden DS, Roberts KJ, Kakinami L, Duan N. A small dose of HIV? HIV vaccine mental models and risk communication. Health Educ Behav. 2009 Apr;36[2]:321–33. doi: 10.1177/1090198107305078 18032589

11. Lesch A, Kafaar Z, and, Swartz L. Community members' perceptions of enablers and inhibitors to participation in HIV vaccine trials. South African Journal of Psychology. 2006;36:734–61.

12. Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, Nanvubya A, et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara [MVA] in humans in East Africa. Vaccine. 2008 May 23;26[22]:2788–95. doi: 10.1016/j.vaccine.2008.02.071 18440674

13. Kibuuka H, Guwatudde D, Kimutai R, Maganga L, Maboko L, Watyema C, et al. Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa. PLoS One. 2009;4[4]:e5164. doi: 10.1371/journal.pone.0005164 19360102

14. Mugerwa RD, Kaleebu P, Mugyenyi P, Katongole-Mbidde E, Hom DL, Byaruhanga R, et al. First trial of the HIV-1 vaccine in Africa: Ugandan experience. BMJ. 2002 Jan 26;324:226–9. doi: 10.1136/bmj.324.7331.226 11809648

15. Mugyenyi PN. HIV vaccines: the Uganda experience. Vaccine. 2002 May 6;20[15]:1905–8. doi: 10.1016/s0264-410x(02)00064-6 11983242

16. Omosa-Manyonyi GS, Jaoko W, Anzala O, Ogutu H, Wakasiaka S, Malogo R, et al. Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya aids vaccine initiative [KAVI], Kenya. PLoS One. 2011;6[1]:e14580. doi: 10.1371/journal.pone.0014580 21283743

17. Inungu NJ, Bender B, Gieber L. Socio-Behavioral Challenges to HIV Vaccine Trials: Literature Review. Clinical Research in HIV/AIDS. 2017;4[1]:1–16.

18. Swartz L, Kagee A. Community participation in AIDS vaccine trials: empowerment or science? Soc Sci Med. 2006 Sep;63[5]:1143–6. doi: 10.1016/j.socscimed.2006.03.032 16707200

19. Lau CY, Swann EM, Singh S, Kafaar Z, Meissner HI, Stansbury JP. Conceptual framework for behavioral and social science in HIV vaccine clinical research. Vaccine. 2011 Oct 13;29[44]:7794–800. doi: 10.1016/j.vaccine.2011.07.108 21821083

20. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS. 2010 Sep;5[5]:357–61. doi: 10.1097/COH.0b013e32833d2d2b 20978374

21. Newman PA, Yim S, Daley A, Walisser R, Halpenny R, Cunningham W, et al. "Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination. Vaccine. 2011 Jan 10;29[3]:451–8. doi: 10.1016/j.vaccine.2010.10.076 21075163

22. Newman PA, Logie C, James L, Charles T, Maxwell J, Salam K, et al. "Speaking the dialect": understanding public discourse in the aftermath of an HIV vaccine trial shutdown. Am J Public Health. 2011 Sep;101[9]:1749–58. doi: 10.2105/AJPH.2011.300208 21778490

23. Newman PA, Rubincam C, Slack C, Essack Z, Chakrapani V, Chuang DM, et al. Towards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An Embedded Four-Country Case Study. PLoS One. 2015;10[8]:e0135937. doi: 10.1371/journal.pone.0135937 26295159

24. Tarimo EA, Thorson A, Kohi TW, Mwami J, Bakari M, Sandstrom E, et al. Balancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania. BMC Public Health. 2010;10:292. doi: 10.1186/1471-2458-10-292 20509908

25. Tarimo EA, Thorson A, Kohi TW, Bakari M, Mhalu F, Kulane A. Reasons for declining to enroll in a phase I and II HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania. PLOS ONE. 2011;6[2]:e14619. doi: 10.1371/journal.pone.0014619 21358826

26. Tarimo EA, Thorson A, Kohi TW, Bakari M, Sandstrom E, Mhalu F, et al. A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania. BMC Infect Dis. 2011;11:283. doi: 10.1186/1471-2334-11-283 22023776

27. Tarimo EA, Munseri P, Aboud S, Bakari M, Mhalu F, Sandstrom E. Experiences of social harm and changes in sexual practices among volunteers who had completed a phase I/II HIV vaccine trial employing HIV-1 DNA priming and HIV-1 MVA boosting in Dar es Salaam, Tanzania. PLoS One. 2014;9[3]:e90938. doi: 10.1371/journal.pone.0090938 24603848

28. Mbunda T, Tarimo EA, Chalamilla G, Bakari M, Sandstrom E, Kulane A. The Influence of Community Members on Participation by Youth in an HIV Vaccine Trial in Tanzania. PLoS One. 2016;11[12]:e0168660. doi: 10.1371/journal.pone.0168660 27997617

29. Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine. 2011 Oct 26;29[46]:8417–28. doi: 10.1016/j.vaccine.2011.08.001 21864626

30. Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, et al. Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial. PLoS One. 2015;10[4]:e0119629. doi: 10.1371/journal.pone.0119629 25875843

31. Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, et al. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. PLoS One. 2018;13[11]:e0206838. doi: 10.1371/journal.pone.0206838 30496299

32. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology,. 2006;3[2]:77–101.

33. Newman PA, Duan N, Roberts KJ, Seiden D, Rudy ET, Swendeman D, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. Journal of acquired immune deficiency syndromes [1999]. 2006 Feb 1;41[2]:210–7.

34. Pitisuttithum P, Choopanya K, Bussaratid V, Vanichseni S, van Griensven F, Phonrat B, et al. Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand. J Med Assoc Thai. 2007 Nov;90[11]:2442–8. 18181333

35. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005 Mar 1;191[5]:654–65. doi: 10.1086/428404 15688278

36. Newman PA, Duan N, Rudy ET, Anton PA. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? AIDS Patient Care STDS. 2004 Dec;18[12]:691–701. doi: 10.1089/apc.2004.18.691 15659880

37. Newman PA, Duan N, Lee SJ, Rudy E, Seiden D, Kakinami L, et al. Willingness to participate in HIV vaccine trials: the impact of trial attributes. Preventive medicine. 2007 Jun;44[6]:554–7. doi: 10.1016/j.ypmed.2006.12.007 17275895

38. Roberts KJ, Newman PA, Duan N, Rudy ET. HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion. J Natl Med Assoc. 2005 Dec;97[12]:1662–71. 16396058

39. Mutua G, Mutengu L, Mpendo J, Kilembe W, Omosa-Manyonyi G, Ruzagira G, et al. Major Negative Social Impacts Are Rare in Phase 1 HIV Vaccine Trials in Africa. AIDS research and human retroviruses; 2014. p. A190–A1.

40. Ott MA, Alexander AB, Lally M, Steever JB, Zimet GD. Preventive misconception and adolescents' knowledge about HIV vaccine trials. J Med Ethics. 2013 Dec;39[12]:765–71. doi: 10.1136/medethics-2012-100821 23355050

41. International Council of AIDS Service Organizations. Community Involvement in HIV vaccine research: making it work.; 2009.

Článek vyšel v časopise


2019 Číslo 11